<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939364</url>
  </required_header>
  <id_info>
    <org_study_id>SBS-101-CL-001</org_study_id>
    <nct_id>NCT03939364</nct_id>
  </id_info>
  <brief_title>This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of SBS-101 After Intraoral Application in Patients With Oral Premalignant Lesions (OPL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skyline Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skyline Biosciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the first study investigating the safety, pharmacokinetics (PK), and&#xD;
      efficacy of SBS-101 on oral pre-malignant lesions. As such, no clinical data has yet been&#xD;
      generated using SBS-101 oral adhesive film.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Delays due to manufacturing and the COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of patients with overall response will be summarized by treatment</measure>
    <time_frame>13 weeks</time_frame>
    <description>Overall response is defined as complete or partial response in either clinical or histological outcome without worsening of either.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentages of patients reporting any treatment-emergent adverse event (AE) will be tabulated by system organ class and preferred term for each treatment</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of isotretinoin will be summarized by treatment using descriptive statistics</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukoplakia, Oral</condition>
  <arm_group>
    <arm_group_label>0.1% SBS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% SBS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2% SBS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBS-101</intervention_name>
    <description>Isotretinoin Oral-Adhesive Film</description>
    <arm_group_label>0.1% SBS-101</arm_group_label>
    <arm_group_label>0.2% SBS-101</arm_group_label>
    <arm_group_label>0.3% SBS-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is able to comprehend and willing to sign an Informed Consent Form.&#xD;
&#xD;
          2. Patient is willing and able to follow all study instructions and to attend all study&#xD;
             visits&#xD;
&#xD;
          3. Patient is male or female aged 18 years or older at Screening.&#xD;
&#xD;
          4. Patient has oral leukoplakia or erythroplakia at least 5mm in length on its longest&#xD;
             axis with histopathology showing mild, moderate, or severe dysplasia (index lesion&#xD;
             histology score of ≥2) with incisional (punch) biopsy at Screening (or within 30 days&#xD;
             prior to Screening).&#xD;
&#xD;
          5. Patient agrees to not use any topical therapies (i.e. use of over the counter and&#xD;
             medically prescribed topical creams, ointments, or oral rinses) on the index lesion&#xD;
             other than the study drug that, in the Investigator's opinion, might influence the&#xD;
             status of the index lesion for the duration of the study.&#xD;
&#xD;
          6. Patient agrees to not apply any other topical products or use potential irritants&#xD;
             (i.e. alcohol containing mouthwash) to the oral premalignant lesions throughout the&#xD;
             study. Note: mouthwash that includes non-alcohol containing formulations of Listerine&#xD;
             and Crest is acceptable to use during the study.&#xD;
&#xD;
          7. If female, patient is non-pregnant, non-lactating and is not planning for pregnancy&#xD;
             during the study period or for 1 month after the last dose of study drug.&#xD;
&#xD;
          8. Female patients of non-childbearing potential must meet the following requirements:&#xD;
&#xD;
               1. Pre-menopausal with documentation of surgical sterilization (i.e., hysterectomy,&#xD;
                  bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy) at&#xD;
                  least 3 months prior to study entry.&#xD;
&#xD;
               2. Post-menopausal defined as amenorrhea for at least 12 months following cessation&#xD;
                  of all exogenous hormonal treatments and with follicle-stimulating hormone (FSH)&#xD;
                  level ≥40 milli-international units per milliliter (mIU/mL) at Screening.&#xD;
&#xD;
          9. Female patients of child-bearing potential must select and commit to use 2 forms of&#xD;
             effective contraception simultaneously, at least 1 of which must be a primary form,&#xD;
             unless absolute abstinence is the chosen method, or the patient has undergone a&#xD;
             hysterectomy. Patients must use 2 forms of effective contraception at least 1 month&#xD;
             prior to study initiation (Screening), during the study, and for 1 month after the&#xD;
             final dose of study drug.&#xD;
&#xD;
             Primary (hormonal or surgical)&#xD;
&#xD;
               1. Tubal ligation&#xD;
&#xD;
               2. Partner's vasectomy&#xD;
&#xD;
               3. Intrauterine devices&#xD;
&#xD;
               4. Birth control pills&#xD;
&#xD;
               5. Injectable/implantable/insertable hormonal birth control products Secondary&#xD;
                  (Barrier Method)&#xD;
&#xD;
               1. Diaphragm (with spermicide)&#xD;
&#xD;
               2. Cervical cap (with spermicide)&#xD;
&#xD;
               3. Male condom (with spermicide)&#xD;
&#xD;
         10. Male patients must agree to use condoms during sexual intercourse during the study and&#xD;
             for 3 months after the final dose of study drug. If a female partner is of&#xD;
             childbearing potential, she should use contraception as detailed in Inclusion&#xD;
             criterion&#xD;
&#xD;
             # 9. Males must also agree to not donate sperm from the time of first dosing and for 3&#xD;
             months after the final dose of study drug.&#xD;
&#xD;
         11. Patient's Eastern Cooperative Oncology Group (ECOG) performance status grade is 0 or 1&#xD;
             at Screening.&#xD;
&#xD;
         12. Patient's organ function is determined to be adequate based on laboratory testing at&#xD;
             Screening (e.g. Hemoglobin levels ≥ 10g/dl; White Blood Cells (WBC) ≥ 3,000/μL;&#xD;
             Platelets ≥ 100,000/μL; Total bilirubin ≤ 1.5x Upper Limit of Normal (ULN); Aspartate&#xD;
             Aminotransferase (AST)/ Alanine aminotransferase (ALT) &lt; 2x Upper Limit of Normal&#xD;
             (ULN);, Blood urea nitrogen (BUN) &amp; serum creatinine ≤ 1.5x Upper Limit of Normal&#xD;
             (ULN); Lactate dehydrogenase (LDH) ≤ 1.5x Upper Limit of Normal (ULN); Glucose &lt; 200&#xD;
             mg/dL; Thyroid Stimulating Hormone (TSH) ≤ 5.0 μU/mL; C-Reactive Protein &lt; 5.0 mg/L).&#xD;
&#xD;
         13. Negative urine drug screen at Screening.&#xD;
&#xD;
         14. Patient is in good general health and free of any known disease state or physical&#xD;
             condition which, in the Investigator's opinion, might impair evaluation of the oral&#xD;
             premalignant lesions or which exposes the patient to an unacceptable risk by&#xD;
             participating in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has oral lesions to be treated that are infected (e.g. lesions that require&#xD;
             local or systemic antimicrobial, antifungal, or antiviral therapy to treat an&#xD;
             infection) within 14 days of Randomization.&#xD;
&#xD;
          2. Patients must not use any systemic (e.g., oral or injectable) corticosteroid therapy&#xD;
             during the study or within 30 days prior to Screening. However, use of topical,&#xD;
             inhaled, ophthalmic, intraarticular and intralesional steroids is permitted.&#xD;
&#xD;
          3. Patient has used any topical or systemic chemotherapeutic product within 30 days prior&#xD;
             to Randomization.&#xD;
&#xD;
          4. Use of smokeless tobacco within 4 weeks prior to Screening or during the course of the&#xD;
             study.&#xD;
&#xD;
          5. Patient has been diagnosed with hairy leukoplakia.&#xD;
&#xD;
          6. Patient has evidence of a systemic infection or has used systemic antibiotics within&#xD;
             14 days prior to start of dosing for males and females of non-childbearing potential&#xD;
             or within 30 days prior to start of dosing for Women of Childbearing Potential&#xD;
             (WOCBP).&#xD;
&#xD;
          7. Patient is currently taking high doses of vitamin A (&gt; 25,000 USP units per day) or&#xD;
             has previously used isotretinoin for the treatment of another condition within 6&#xD;
             months of Screening.&#xD;
&#xD;
          8. Patient is currently taking phenytoin or other prohibited medication&#xD;
&#xD;
          9. Patient's index lesion is a recurrent dysplastic lesion in a previously treated area&#xD;
             for oral cancer (previous treatment, bed/excision, etc.).&#xD;
&#xD;
         10. The patient has received radiation or chemoradiation therapy to oral cavity within 2&#xD;
             years of Randomization.&#xD;
&#xD;
         11. The patient has any immune compromising conditions at Screening (i.e. HIV, SLE, etc.)&#xD;
             or has been treated with immunomodulating medications within 6 months of Screening.&#xD;
&#xD;
         12. Patient currently has poorly controlled diabetes mellitus (uninterrupted hemoglobin&#xD;
             A1c &gt;9% for ≥1 year despite standard care).&#xD;
&#xD;
         13. Patient has a history of cardiac, hepatic (ALT and or AST &gt;2x ULN, Total bilirubin&#xD;
             &gt;1.5x ULN at Visit 1), or renal disease (eGFR&lt;45 ml/min/1.73 m2) that, in the opinion&#xD;
             of the Investigator, might put the patient at undue risk by participating in the study&#xD;
             or interferes with the study drug application or the study assessments.&#xD;
&#xD;
         14. Patient has a history of sensitivity to any of the active ingredients in the study&#xD;
             drug (e.g. isotretinoin, propylene glycol, natural mint), or retinoids, or vitamin A.&#xD;
&#xD;
         15. Patient has used oral isotretinoin within 14 days of Screening. Patients must agree to&#xD;
             abstain from using oral isotretinoin throughout the duration in the study.&#xD;
&#xD;
         16. Patient has participated in an investigational drug trial in which administration of&#xD;
             an investigational study drug occurred within 30 days prior to Randomization.&#xD;
&#xD;
         17. Patient is, in the opinion of the Investigator, not an appropriate candidate for study&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy Schleyer</last_name>
    <role>Study Director</role>
    <affiliation>Skyline Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center for Oral Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PennState Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Oral &amp; Maxillofacial Surgery Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythroplakia, oral</keyword>
  <keyword>Erythro-leukoplakia, oral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

